IME

8.89%

49.0¢ imexhs limited

Ann: Quarterly Cash Flow and Summary of Activities, page-42

First 42 Last

Share
Profile

Follow
TitusPullo

4,694 Posts.

72

23/10/19

15:02

Post #: 41032604
Share

Originally posted by Just_a_guy ↑

i was initially very interested in ime because of South America/developing world.
They have a clear first mover advantage in South America and as the presentation suggests, they are replacing archaic systems including wet film. This provides a great tailwind.

So why on earth are they wasting time and money on aus and America? They don’t have a hope of competing in those markets. The cost of pacs/ris for a radiology clinic is a tiny tiny fraction of revenue in developed countries, and therefore radiology providers are going to favour efficiency over cost (except sometimes in the public health sector in aus but care stream and cdn are competitors in that space too). So ime trying to undercut their bigger competitors who have more scale means they are up against an impossible task in my view. They can’t be the most functional or efficient provider because the r&d spend of their competitors is many multiples of ime’s revenue.

Cybically, i think they are signing up a hicksville mobile ultrasound company in aus and applying for fda to help their share price to help them raise capital.

so that brings us back to South America. I think ime has a chance of doing very well if their product is reasonable (which I highly doubt given that they were touting ‘new cross referencing ability’ 12 months ago, which is a feature that the better provider have been providing for more then a decade).
If they can keep signing up hospitals in South America and the developing world while the big competitors concentrate on the growing developed world, then they will do well. But the second a better competitor comes along, due to scalability of the software which is increasing by the year, I believe ime will be cactus, and I don’t think carestream/pme/intelerad will need to bother buying ime.

Having said that there is every chance ime 5bags prior, but I just don’t think they have a long term business, and buying this hoping a competitor buys them is rarely a strategy for success.

Expand

Justaguy In a teleconference a few months back IME's management explained that getting FDA approval and having soft launches in the USA and Oz was more about assisting with making it easier to win contracts in South America. They realised their resources were not sufficient to really tackle the USA and Oz. Maybe those plans have changed since, hence the CR.......though I hope not. Look back through some posts and questions raised by Composer and the replies, as a few were on the teleconference were this was discussed.

IME Price at posting: 4.1¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

RCE

Recce's R327 found effective against E.coli during clinical trial

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

There are more pages in this discussion • 90 more messages in this thread...

First 42 Last

Add IME (ASX) to my watchlist

(20min delay)
Last 49.0¢		Change 0.040(8.89%)		Mkt cap ! $22.31M

Open	High	Low	Value	Volume
45.0¢	49.0¢	45.0¢	$18.44K	40K

Buyers (Bids)

No.	Vol.	Price($)
1	20000	43.0¢

Sellers (Offers)

Price($)	Vol.	No.
45.0¢	8300	1

View Market Depth

No.	Vol.	Price($)
1	20000	0.430
1	10000	0.400
1	2703	0.370
1	13888	0.360
0	0	0.000

Price($)	Vol.	No.
0.450	8300	1
0.480	7012	1
0.500	20000	1
0.550	18000	1
0.605	12727	1

Last trade - 15.59pm 28/06/2024 (20 minute delay)

IME (ASX) Chart

Ann: Quarterly Cash Flow and Summary of Activities, page-42

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Cash Flow and Summary of Activities, page-42

Top Stories

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News